When to keep it simple - adaptive designs are not always useful

被引:48
作者
Wason, James M. S. [1 ,2 ]
Brocklehurst, Peter [3 ]
Yap, Christina [4 ,5 ]
机构
[1] Newcastle Univ, Inst Hlth & Soc, Baddiley Clark Bldg,Richardson Rd, Newcastle Upon Tyne NE2 4AX, Tyne & Wear, England
[2] Univ Cambridge, MRC Biostat Unit, Cambridge, England
[3] Univ Birmingham, Birmingham Clin Trials Unit, Birmingham, W Midlands, England
[4] Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England
[5] Inst Canc Res, Clin Trials & Stat Unit, London, England
基金
英国医学研究理事会;
关键词
Adaptive design; Clinical trials; Efficiency; Patient benefit; CLINICAL-TRIALS;
D O I
10.1186/s12916-019-1391-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundAdaptive designs are a wide class of methods focused on improving the power, efficiency and participant benefit of clinical trials. They do this through allowing information gathered during the trial to be used to make changes in a statistically robust manner - the changes could include which treatment arms patients are enrolled to (e.g. dropping non-promising treatment arms), the allocation ratios, the target sample size or the enrolment criteria of the trial. Generally, we are enthusiastic about adaptive designs and advocate their use in many clinical situations. However, they are not always advantageous. In some situations, they provide little efficiency advantage or are even detrimental to the quality of information provided by the trial. In our experience, factors that reduce the efficiency of adaptive designs are routinely downplayed or ignored in methodological papers, which may lead researchers into believing they are more beneficial than they actually are.Main textIn this paper, we discuss situations where adaptive designs may not be as useful, including situations when the outcomes take a long time to observe, when dropping arms early may cause issues and when increased practical complexity eliminates theoretical efficiency gains.ConclusionAdaptive designs often provide notable efficiency benefits. However, it is important for investigators to be aware that they do not always provide an advantage. There should always be careful consideration of the potential benefits and disadvantages of an adaptive design.
引用
收藏
页数:7
相关论文
共 20 条
  • [1] Early stopping of randomized clinical trials for overt efficacy is problematic
    Bassler, Dirk
    Montori, Victor M.
    Briel, Matthias
    Glasziou, Paul
    Guyatt, Gordon
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2008, 61 (03) : 241 - 246
  • [2] Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov
    Bothwell, Laura E.
    Avorn, Jerry
    Khan, Nazleen F.
    Kesselheim, Aaron S.
    [J]. BMJ OPEN, 2018, 8 (02):
  • [3] Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials
    Dimairo, Munyaradzi
    Boote, Jonathan
    Julious, Steven A.
    Nicholl, Jonathan P.
    Todd, Susan
    [J]. TRIALS, 2015, 16
  • [4] The price of innovation: new estimates of drug development costs
    DiMasi, JA
    Hansen, RW
    Grabowski, HG
    [J]. JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) : 151 - 185
  • [5] Surrogate end points in clinical trials: Are we being misled?
    Fleming, TR
    DeMets, DL
    [J]. ANNALS OF INTERNAL MEDICINE, 1996, 125 (07) : 605 - 613
  • [6] Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design
    Gerety, E. L.
    Lawrence, E. M.
    Wason, J.
    Yan, H.
    Hilborne, S.
    Buscombe, J.
    Cheow, H. K.
    Shaw, A. S.
    Bird, N.
    Fife, K.
    Heard, S.
    Lomas, D. J.
    Matakidou, A.
    Soloviev, D.
    Eisen, T.
    Gallagher, F. A.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (10) : 2113 - 2118
  • [7] Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development
    Gu X.
    Chen N.
    Wei C.
    Liu S.
    Papadimitrakopoulou V.A.
    Herbst R.S.
    Lee J.J.
    [J]. Statistics in Biosciences, 2016, 8 (1) : 99 - 128
  • [8] Adaptive designs undertaken in clinical research: a review of registered clinical trials
    Hatfield, Isabella
    Allison, Annabel
    Flight, Laura
    Julious, Steven A.
    Dimairo, Munyaradzi
    [J]. TRIALS, 2016, 17
  • [9] Are outcome-adaptive allocation trials ethical?
    Hey, Spencer Phillips
    Kimmelman, Jonathan
    [J]. CLINICAL TRIALS, 2015, 12 (02) : 8 - 12
  • [10] Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
    James, Nicholas D.
    Sydes, Matthew R.
    Clarke, Noel W.
    Mason, Malcolm D.
    Dearnaley, David P.
    Spears, Melissa R.
    Ritchie, Alastair W. S.
    Parker, Christopher C.
    Russell, J. Martin
    Attard, Gerhardt
    de Bono, Johann
    Cross, William
    Jones, Rob J.
    Thalmann, George
    Amos, Claire
    Matheson, David
    Millman, Robin
    Alzouebi, Mymoona
    Beesley, Sharon
    Birtle, Alison J.
    Brock, Susannah
    Cathomas, Richard
    Chakraborti, Prabir
    Chowdhury, Simon
    Cook, Audrey
    Elliott, Tony
    Gale, Joanna
    Gibbs, Stephanie
    Graham, John D.
    Hetherington, John
    Hughes, Robert
    Laing, Robert
    McKinna, Fiona
    McLaren, Duncan B.
    O'Sullivan, Joe M.
    Parikh, Omi
    Peedell, Clive
    Protheroe, Andrew
    Robinson, Angus J.
    Srihari, Narayanan
    Srinivasan, Rajaguru
    Staffurth, John
    Sundar, Santhanam
    Tolan, Shaun
    Tsang, David
    Wagstaff, John
    Parmar, Mahesh K. B.
    [J]. LANCET, 2016, 387 (10024) : 1163 - 1177